Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ESGO 2021
It was great to speak with Marcelo Bonomi at #ASCO26 to discuss findings from a Phase II trial of metronomic carboplatin and paclitaxel with cemiplimab in R/M #HNSCC 💉
The combination showed meaningful antitumor activity and cytokine profiling indicated immune-mediated
🎙️ Explore #WCLC26 highlights in this week’s VJOncology podcast, covering highly anticipated trials such as PAPILLON and REZILIENT 3, updates in #SCLC and #mesothelioma, and more! Listen now for expert insights from Seoul! ▶️
🔗https://www.vjoncology.com/podcast/lung-cancer-highlights-from-wclc-2026/
🍎 Apple Podcasts:
In a recent interview at #WCLC26, Massimiliano Cani explores results from the RISP trial evaluating cytisine for smoking cessation in older adults 🫁 🚬🚫
Watch:
#Oncology #LungCancer #LCSM @IASLC
This video is available on the Lung Cancer Channel on
RISP: cytisine for smoking cessation in patients over the age of 65
Massimiliano Cani, MD, University of Turin, Turin, Italy, discusses results from the RISP trial (NCT05766046), evaluatin...
ow.ly
#ASCO26 | Choong-kun Lee explores data from the HERBOT trial of 1L trastuzumab with nivolumab, gemcitabine and cisplatin in HER2+ #BiliaryTractCancer 📊 The study met the primary endpoint, improving ORR and DCR, and showed a manageable safety profile 🧬🩺
Watch:
How does MTAP deletion and PRMT5 expression affect outcomes in #NSCLC? 🔬
Robert Hsu (@md_hsu) explores this in a recent interview at #WCLC26 💡🫁
Watch:
#Oncology #LungCancer #LCSM @IASLC
MTAP deletion and PRMT5 expression predict poor outcomes in NSCLC
Robert Hsu, MD, University of Southern California, Los Angeles, CA, discusses the clinical relevance of MTAP deletions...
ow.ly
ESGO 2021
It was great to speak with Marcelo Bonomi at #ASCO26 to discuss findings from a Phase II trial of metronomic carboplatin and paclitaxel with cemiplimab in R/M #HNSCC 💉
The combination showed meaningful antitumor activity and cytokine profiling indicated immune-mediated
🎙️ Explore #WCLC26 highlights in this week’s VJOncology podcast, covering highly anticipated trials such as PAPILLON and REZILIENT 3, updates in #SCLC and #mesothelioma, and more! Listen now for expert insights from Seoul! ▶️
🔗https://www.vjoncology.com/podcast/lung-cancer-highlights-from-wclc-2026/
🍎 Apple Podcasts:
In a recent interview at #WCLC26, Massimiliano Cani explores results from the RISP trial evaluating cytisine for smoking cessation in older adults 🫁 🚬🚫
Watch:
#Oncology #LungCancer #LCSM @IASLC
This video is available on the Lung Cancer Channel on
RISP: cytisine for smoking cessation in patients over the age of 65
Massimiliano Cani, MD, University of Turin, Turin, Italy, discusses results from the RISP trial (NCT05766046), evaluatin...
ow.ly
#ASCO26 | Choong-kun Lee explores data from the HERBOT trial of 1L trastuzumab with nivolumab, gemcitabine and cisplatin in HER2+ #BiliaryTractCancer 📊 The study met the primary endpoint, improving ORR and DCR, and showed a manageable safety profile 🧬🩺
Watch:
How does MTAP deletion and PRMT5 expression affect outcomes in #NSCLC? 🔬
Robert Hsu (@md_hsu) explores this in a recent interview at #WCLC26 💡🫁
Watch:
#Oncology #LungCancer #LCSM @IASLC
MTAP deletion and PRMT5 expression predict poor outcomes in NSCLC
Robert Hsu, MD, University of Southern California, Los Angeles, CA, discusses the clinical relevance of MTAP deletions...
ow.ly
